Back to search

University of Thessaly (UTH)

Δίκτυα θεραπειών για χρόνια νοσήματα και επίδραση της φαρμακογενωμικής: κλινική και μεθοδολογική προσέγγιση

Abstract

dc:description

Chronic diseases require the administration of different treatments depending on the severity and the choice of the appropriate medication remains a challenge. The available randomized controlled trials typically compare only a limited number of treatments or they use placebo as a comparator and thus the use of novel statistical methods such as network meta-analysis may facilitate the selection of the most effective and safe treatment. Additionally, the variable response of patients to treatment with some factors leads to the need for identification of those genetic traits that may affect the response to treatment.The aim of this PhD thesis was to compare different therapies in Crohn's disease, asthma, and multiple sclerosis as well as the search for genetic markers that may influence the effect of these treatments. Per disease, a systematic literature search, extraction of the relevant data from the studies, assessment of the methodological quality of the studies and synthesis of the results using statistical methods were conducted. In moderate to severe Crohn's disease, a systematic search for randomized controlled trials comparing monoclonal antibodies against tumor necrosis factor-alpha (TNF-a) or agents against integrin with placebo and synthesis of their results with the method of network meta-analysis were performed. In the present network meta-analysis of indirect comparisons of anti–TNF-α and anti-integrin agents, a nonsignificant difference was observed between the two drug classes with regards to either induction or maintenance of clinical response or remission. The relative efficacy and safety of various leukotriene receptor antagonists in the treatment of asthma had not been investigated. The meta-analysis showed that administration of LTRAs to adults and adolescents with asthma significantly reduced the risk for an exacerbation and this treatment effect was consistent across all types of LTRAs. The relative efficacy and safety profile of the treatments with marketing authorization for multiple sclerosis were examined using network meta-analysis. No treatment was found superior in all outcome measures of interest. Finally, a possible relationship between the genetic polymorphism FcgRIIIA-158 V/F in patients with Crohn's disease and response to treatment with infliximab was investigated. The synthesis of the results of three pharmacogenetic studies using the generalized odds ratio did not reveal any statistically significant association.In conclusion, the present findings of the synthesis of randomized controlled trials with novel statistical methods may assist therapeutic decisions in choosing the most appropriate treatment, always taking into account the specific characteristics of each patient.

Degree

thesis:*
Grantor dc:publisher
University of Thessaly (UTH)
Year dc:date
2016

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Miligkos, Michail
  • Μηλίγκος, Μιχαήλ

Subjects

dc:subject × 8

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/38565

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Miligkos, Michail; Μηλίγκος, Μιχαήλ. Δίκτυα θεραπειών για χρόνια νοσήματα και επίδραση της φαρμακογενωμικής: κλινική και μεθοδολογική προσέγγιση. University of Thessaly (UTH), 2016. http://hdl.handle.net/10442/hedi/38565